AB-1002 (Bayer AG) is an investigational one-time gene therapy administered via intracoronary artery infusion to reduce symptoms of advanced nonischemic heart failure.
AB-1002 (Bayer AG) is an investigational one-time gene therapy administered via intracoronary artery infusion to reduce symptoms of advanced nonischemic heart failure.